DeDora Capital Inc. Acquires Shares of 1,221 CME Group Inc. (NASDAQ:CME)

DeDora Capital Inc. purchased a new stake in CME Group Inc. (NASDAQ:CME - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,221 shares of the financial services provider's stock, valued at approximately $324,000.

Several other large investors have also modified their holdings of CME. Norges Bank purchased a new stake in CME Group during the 4th quarter worth about $1,107,389,000. Price T Rowe Associates Inc. MD increased its holdings in CME Group by 89.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,280,785 shares of the financial services provider's stock worth $1,923,047,000 after purchasing an additional 3,921,278 shares during the period. GAMMA Investing LLC increased its holdings in CME Group by 32,941.0% during the 1st quarter. GAMMA Investing LLC now owns 1,858,887 shares of the financial services provider's stock worth $493,144,000 after purchasing an additional 1,853,261 shares during the period. Franklin Resources Inc. increased its holdings in shares of CME Group by 38.7% in the 4th quarter. Franklin Resources Inc. now owns 3,366,786 shares of the financial services provider's stock valued at $781,869,000 after acquiring an additional 939,679 shares during the last quarter. Finally, Bessemer Group Inc. increased its holdings in shares of CME Group by 4,216.2% in the 4th quarter. Bessemer Group Inc. now owns 922,805 shares of the financial services provider's stock valued at $214,301,000 after acquiring an additional 901,425 shares during the last quarter. Institutional investors and hedge funds own 87.75% of the company's stock.

CME Group Price Performance

CME stock traded up $1.84 during midday trading on Wednesday, hitting $276.48. 2,665,644 shares of the stock were exchanged, compared to its average volume of 2,190,852. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.02 and a current ratio of 1.02. The stock's 50-day moving average price is $275.89 and its 200-day moving average price is $261.04. The stock has a market cap of $99.63 billion, a price-to-earnings ratio of 27.81, a PEG ratio of 4.82 and a beta of 0.44. CME Group Inc. has a fifty-two week low of $193.25 and a fifty-two week high of $290.79.

CME Group (NASDAQ:CME - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.91 by $0.05. The company had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.68 billion. CME Group had a return on equity of 14.03% and a net margin of 57.71%. CME Group's revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.56 earnings per share. Research analysts predict that CME Group Inc. will post 10.49 earnings per share for the current year.

CME Group Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th were given a $1.25 dividend. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.81%. The ex-dividend date of this dividend was Monday, June 9th. CME Group's dividend payout ratio is currently 50.30%.

Insider Activity

In other CME Group news, General Counsel Jonathan L. Marcus sold 390 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $277.50, for a total transaction of $108,225.00. Following the transaction, the general counsel owned 6,708 shares in the company, valued at $1,861,470. The trade was a 5.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel G. Kaye sold 500 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $282.42, for a total value of $141,210.00. Following the completion of the transaction, the director owned 3,668 shares in the company, valued at approximately $1,035,916.56. This trade represents a 12.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,400 shares of company stock valued at $3,680,610 in the last 90 days. 0.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Barclays increased their price objective on CME Group from $283.00 to $299.00 and gave the company an "equal weight" rating in a report on Thursday, July 10th. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $269.00 price objective on shares of CME Group in a research report on Thursday, April 3rd. JPMorgan Chase & Co. decreased their price objective on CME Group from $223.00 to $211.00 and set an "underweight" rating for the company in a research report on Thursday, April 24th. Erste Group Bank cut CME Group from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Keefe, Bruyette & Woods increased their price objective on CME Group from $265.00 to $273.00 and gave the stock a "market perform" rating in a research report on Thursday, April 24th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $261.80.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.